Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy and bone marrow transplantation

H P Kiem1, C von Kalle, F Schuening

  • 1Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Current Opinion in Oncology
|March 1, 1995
PubMed
Summary

Retrovirus gene transfer into hematopoietic stem cells is efficient in mice but not humans. Enhancements improve *in vitro* transduction, but *in vivo* efficacy for stem cell therapy requires further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.

ESMO open·2025
Same author

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).

Infection·2021
Same author

Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency.

Scientific reports·2018
Same author

Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.

Nature communications·2017
Same author

Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • * Hematopoietic stem cell (HSC) research
  • * Gene therapy and retroviral vectors
  • * Comparative animal and human studies

Background:

  • * Retrovirus-mediated gene transfer into HSCs is established in mice, but efficiency is low in humans and large animals.
  • * Low transduction efficiency hinders therapeutic applications of gene transfer in humans.
  • * Current gene marking studies in humans and large animals utilize observed efficiencies of 0.1% to 1%.

Purpose of the Study:

  • * To review methods for improving retrovirus-mediated gene transfer into human and large animal hematopoietic progenitor cells.
  • * To assess the potential of these methods for enhancing transduction of pluripotent HSCs.
  • * To evaluate the current efficiency of HSC transduction for gene marking and therapeutic applications.

Main Methods:

Related Experiment Videos

  • * Review of *in vitro* studies enhancing retroviral transduction of hematopoietic progenitor cells.
  • * Analysis of methods including CD34+ cell enrichment, growth factor addition, extended exposure times, and pseudotyping with gibbon ape leukemia virus envelope.
  • * Discussion of the need for *in vivo* transplantation studies to confirm effects on pluripotent HSCs.

Main Results:

  • * *In vitro* methods significantly improve transduction efficiency in hematopoietic progenitor cells from large animals and humans.
  • * Specific enhancements include CD34+ cell enrichment, growth factor use, prolonged retrovirus exposure, and gibbon ape leukemia virus envelope pseudotyping.
  • * The impact of these enhancements on *in vivo* pluripotent HSC transduction remains to be determined.

Conclusions:

  • * Current *in vitro* strategies enhance gene transfer into hematopoietic progenitor cells, but their effect on pluripotent HSCs requires *in vivo* validation.
  • * Observed transduction efficiencies (0.1%–1%) are adequate for gene marking but insufficient for widespread therapeutic use.
  • * Further increases in transduction efficiency are necessary to realize the full therapeutic potential of HSC gene transfer.